Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137693 · ClinicalTrials.gov registry record · NA
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03137693 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT03137693, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The type of radiation is called stereotactic ablative body radiation therapy (SABR). The purpose of this study is to evaluate the effects, good and/or bad, of pre-operative SABR specifically focusing on its ability to reduce the chances that additional breast surgery will be needed, reducing the amount of breast/heart/lung tissue that is irradiated, and to study the tumor-tissue effects of SABR. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
Interventions
- OTHER Standard of Care Schedule Variation: SABR
- PROCEDURE Breast-conserving Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2020-01-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137693
The ClinicalTrials.gov registry entry for NCT03137693 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care Schedule Variation: SABR is the first listed.
NCT03137693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137693 about?
NCT03137693 is a clinical study titled "Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer". This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The type of radiation is called stereotactic ablative body radiation therapy (SABR). The purpose of this study is to evaluate the effects, good and/or bad, of pre-operative SABR specifically focusing on its abil...
What is the current status of trial NCT03137693?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2017-11-29. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT03137693?
The interventions under investigation include: Standard of Care Schedule Variation: SABR (OTHER), Breast-conserving Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03137693?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.